Company & track record

Redbiotec is a privately held biotechnology company based in Zurich-Schlieren. Founded in 2006 as a spin-off of ETH Zürich, the company has won several awards, including the renowned W.A. de Vigier Award.

In 2015, Pfizer acquired Redvax GmbH – a spin-off from Redbiotec – for its CMV vaccine program and a vaccine technology platform [press release]. Redbiotec has closed other deals with pharmaceutical companies across Asia, Europe and the U.S.

Redbiotec is backed by experienced institutional and private investors. Select key investors include Zürcher Kantonalbank (ZKB Group) – Switzerland’s largest cantonal bank with S&P AAA credit rating since 1994, and Redalpine Capital, a European seed and early-stage venture investor.

Our values

Scientific leadership

We are committed to developing the best engineered microorganisms and proteins to serve unmet patient needs.

Respect and challenge

We respect and we challenge our competitors, employees, partners and shareholders alike.

Teamwork and constructive criticism

Our people build Redbiotec. We value teamwork as much as being critical individuals.